Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 47.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,340 shares of the biopharmaceutical company’s stock after buying an additional 1,069 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $639,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC boosted its position in shares of Alnylam Pharmaceuticals by 9.1% in the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 363 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Alnylam Pharmaceuticals by 5.1% during the 3rd quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock worth $2,198,000 after buying an additional 598 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Alnylam Pharmaceuticals by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,607 shares of the biopharmaceutical company’s stock worth $4,004,000 after buying an additional 2,201 shares during the period. IFM Investors Pty Ltd boosted its holdings in Alnylam Pharmaceuticals by 2.0% in the third quarter. IFM Investors Pty Ltd now owns 24,871 shares of the biopharmaceutical company’s stock valued at $4,405,000 after acquiring an additional 494 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Alnylam Pharmaceuticals by 3.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 60,719 shares of the biopharmaceutical company’s stock valued at $10,739,000 after acquiring an additional 2,268 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $2.04 during trading hours on Wednesday, hitting $152.29. 451,069 shares of the company were exchanged, compared to its average volume of 750,047. The stock has a market capitalization of $19.26 billion, a price-to-earnings ratio of -56.82 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $218.88. The business’s 50-day simple moving average is $149.35 and its two-hundred day simple moving average is $164.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same period in the prior year, the business earned ($1.40) EPS. The company’s quarterly revenue was up 54.8% on a year-over-year basis. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ALNY shares. Royal Bank of Canada reiterated an “outperform” rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. BMO Capital Markets restated an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $216.19.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.